Peringatan Keamanan

No data is available regarding overdosage with relatlimab.

Relatlimab

DB14851

biotech approved investigational

Deskripsi

Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3).A246165,L41265 It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013,A246155 and has garnered interest in the treatment of a variety of cancers, including leukemiaA246160 and melanoma.L41305 As immune checkpoint inhibitors have limited efficacy when used alone, drugs like relatlimab have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like nivolumab or CTLA-4 inhibitors like ipilimumab - to enhance their efficacy.A246155

Relatlimab received FDA approval in March 2022, alongside the PD-1 inhibitor nivolumab in the combination product Opdualag (Bristol-Myers Squibb), for the treatment of unresectable or metastatic melanoma.L41265,L41300 It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval.L41300 Opdualag was subsequently approved in the European Union in July 2022L49996 and in Canada in September 2023.L50001

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The geometric mean effective half-life of relatlimab, when administered alongside nivolumab, is 26.2 days.[L41265]
Volume Distribusi The geometric mean volume of distribution of relatlimab at steady-state is 6.6 liters.[L41265]
Klirens (Clearance) At steady-state, the geometric mean clearance of relatlimab is 5.5 mL/h.[L41265] Clearance at steady-state appears to be approximately 10% lower than after the first dose.[L41265]

Absorpsi

Following once-monthly administration alongside nivolumab, steady-state concentrations of relatlimab were reached after 16 weeks.L41265 At the recommended dosage, the Cmax and Cavg of relatlimab at steady-state were 62.2 µg/mL and 28.8 µg/mL, respectively.L41265

Metabolisme

As with other therapeutic proteins, the metabolism of relatlimab likely occurs via non-specific catabolism to smaller peptides and amino acids.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

410 Data
Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Relatlimab.
Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Relatlimab.
Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Relatlimab.
Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Relatlimab.
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Relatlimab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Relatlimab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Relatlimab.
Estrone Estrone may increase the thrombogenic activities of Relatlimab.
Estradiol Estradiol may increase the thrombogenic activities of Relatlimab.
Dienestrol Dienestrol may increase the thrombogenic activities of Relatlimab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Relatlimab.
Mestranol Mestranol may increase the thrombogenic activities of Relatlimab.
Estriol Estriol may increase the thrombogenic activities of Relatlimab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Relatlimab.
Quinestrol Quinestrol may increase the thrombogenic activities of Relatlimab.
Hexestrol Hexestrol may increase the thrombogenic activities of Relatlimab.
Tibolone Tibolone may increase the thrombogenic activities of Relatlimab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Relatlimab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Relatlimab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Relatlimab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Relatlimab.
Zeranol Zeranol may increase the thrombogenic activities of Relatlimab.
Equol Equol may increase the thrombogenic activities of Relatlimab.
Estetrol Estetrol may increase the thrombogenic activities of Relatlimab.
Promestriene Promestriene may increase the thrombogenic activities of Relatlimab.
Methallenestril Methallenestril may increase the thrombogenic activities of Relatlimab.
Epimestrol Epimestrol may increase the thrombogenic activities of Relatlimab.
Moxestrol Moxestrol may increase the thrombogenic activities of Relatlimab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Relatlimab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Relatlimab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Relatlimab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Relatlimab.
Biochanin A Biochanin A may increase the thrombogenic activities of Relatlimab.
Formononetin Formononetin may increase the thrombogenic activities of Relatlimab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Relatlimab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Relatlimab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Relatlimab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Relatlimab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Relatlimab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Relatlimab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Relatlimab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Relatlimab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Relatlimab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Relatlimab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Relatlimab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Relatlimab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Relatlimab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Relatlimab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Relatlimab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Relatlimab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Relatlimab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Relatlimab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Relatlimab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Relatlimab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Relatlimab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Relatlimab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Relatlimab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Relatlimab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Relatlimab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Relatlimab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Relatlimab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Relatlimab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Relatlimab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Relatlimab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Relatlimab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Relatlimab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Relatlimab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Relatlimab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Relatlimab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Relatlimab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Relatlimab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Relatlimab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Relatlimab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Relatlimab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Relatlimab.
Hepatitis B immune globulin The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Relatlimab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Relatlimab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Relatlimab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Relatlimab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Relatlimab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Relatlimab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Relatlimab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Relatlimab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Relatlimab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Relatlimab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Relatlimab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Relatlimab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Relatlimab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Relatlimab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Relatlimab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Relatlimab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Relatlimab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Relatlimab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Relatlimab.
Stamulumab The risk or severity of adverse effects can be increased when Stamulumab is combined with Relatlimab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Relatlimab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Relatlimab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Relatlimab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Relatlimab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Relatlimab.

Target Protein

Lymphocyte activation gene 3 protein LAG3

Referensi & Sumber

Artikel (PubMed)
  • PMID: 31242068
    Yu X, Huang X, Chen X, Liu J, Wu C, Pu Q, Wang Y, Kang X, Zhou L: Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy. MAbs. 2019 Aug/Sep;11(6):1139-1148. doi: 10.1080/19420862.2019.1629239. Epub 2019 Jun 26.
  • PMID: 33925565
    Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez AP, Payer AR, Gonzalez-Garcia E, Lopez-Soto A, Gonzalez S: LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia. Cancers (Basel). 2021 Apr 27;13(9). pii: cancers13092112. doi: 10.3390/cancers13092112.
  • PMID: 32929051
    Maruhashi T, Sugiura D, Okazaki IM, Okazaki T: LAG-3: from molecular functions to clinical applications. J Immunother Cancer. 2020 Sep;8(2). pii: jitc-2020-001014. doi: 10.1136/jitc-2020-001014.

Contoh Produk & Brand

Produk: 3 • International brands: 0
Produk
  • Opdualag
    Injection, solution, concentrate • - • Intravenous • EU • Approved
  • Opdualag
    Solution • - • Intravenous • Canada • Approved
  • Opdualag
    Injection • - • Intravenous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul